Description
| Description | VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties. |
| In vitro | VGX-1027 enhances survival rates and ameliorates clinical and histopathological signs in the NZB/NZW F1 model of systemic lupus erythematosus, thereby improving disease progression. It prevents the spontaneous development of Type 1 diabetes in NOD mice and counters the acceleration of diabetes induced either by cyclophosphamide assault or by the adoptive transfer of diabetogenic spleen cells in NOD mice. Furthermore, VGX-1027 reduces clinical symptoms of diabetes induced by MLD-STZ and inhibits pathological histological changes in the pancreas. |
| In vivo | VGX-1027 exhibits inhibitory effects on the proliferation of gut bacterial antigen-reactive CD4+ CD25- T cells in vitro. It significantly suppresses the accumulation of TNF-α and nitrites induced by IL-1β/IFN-γ, and notably enhances cell survival by interfering with the toxic effects of cytokines. |
| Synonyms | VGX1027, VGX 1027, GIT 27 |
| Molecular Weight |
205.21 |
| Formula | C11H11NO3 |
| CAS No. | 6501-72-0 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 20.5 mg/mL (100 mM)
